The review emphasizes the critical need for approved pharmacological treatments for severe hypertriglyceridemia in children, as current management relies heavily on off-label therapies and invasive procedures.
No approved TG-lowering drugs for children; leaves open urgent need for pediatric-specific trials.
The clinical picture of familial chylomicronemia syndrome (FCS) affects children and adolescents, with a higher prevalence in children younger than 1 year of life. With breastfeeding and accumulation of chylomicron in the circulation, severe hypertriglyceridemia (SHTG) and onset of symptoms may develop in a period of days to months.
No takes yet. Share an insight, caveat, or question.
Tânia Leme da Rocha Martinez (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: